Paul Sakorafas

Pfizer (United States) — United States

Medicine · Health Sciences

12h-index1.4kcitations18works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(10), Glycosylation and Glycoproteins Research(7), Protein purification and stability(3), Viral Infectious Diseases and Gene Expression in Insects(3), T-cell and B-cell Immunology(2)

Publications18 total

Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activation
Journal of Biotechnology·2022· 3 citedOpen Access
Small-molecule control of antibody N-glycosylation in engineered mammalian cells
Nature Chemical Biology·2019· 71 cited
Establishing <i>in vitro in vivo</i> correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
mAbs·2017· 97 citedOpen Access
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Blood·2012· 153 cited
Pulmonary Administration of Interferon Beta-1a-Fc Fusion Protein in Non-Human Primates Using an Immunoglobulin Transport Pathway
Journal of Interferon & Cytokine Research·2011· 29 cited
X-ray Crystal Structures of Monomeric and Dimeric Peptide Inhibitors in Complex with the Human Neonatal Fc Receptor, FcRn
Journal of Biological Chemistry·2010· 41 citedOpen Access
Crystal structure of human FcRn with a monomeric peptide inhibitor
2010
Synthesis and Structure−Activity Relationships of Dimeric Peptide Antagonists of the Human Immunoglobulin G−Human Neonatal Fc Receptor (IgG−FcRn) Interaction
Journal of Medicinal Chemistry·2010· 10 citedOpen Access
Expression of antibodies using single‐open reading frame vector design and polyprotein processing from mammalian cells
Biotechnology Progress·2009· 8 citedOpen Access
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Clinical Immunology·2009· 309 cited
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Nature Biotechnology·2007· 335 cited
Determination of affinity constants of adalimumab, infliximab and etanercept for soluble and membrane forms of TNF using kinetic exclusion assay (131.22)
The Journal of Immunology·2007· 3 cited
F.69. Etanercept, Infliximab and Adalimumb Bind to Soluble and Transmembrane TNF with Similar Affinities
Clinical Immunology·2006· 2 cited
IL-18 Receptor β-Induced Changes in the Presentation of IL-18 Binding Sites Affect Ligand Binding and Signal Transduction
The Journal of Immunology·2003· 53 citedOpen Access
Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIAcore
Analytical Biochemistry·2001· 106 cited
LPAP, a novel 32-kDa phosphoprotein that interacts with CD45 in human lymphocytes.
Journal of Biological Chemistry·1994· 72 citedOpen Access
The use of microcapsules for high density growth of human tumor infiltrating lymphocytes and other immune reactive T cells
Journal of Immunological Methods·1990· 12 cited
Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice
Clinical Immunology and Immunopathology·1988· 51 cited

Frequent Co-authors

Sahana Bose(4), Zehra Kaymakcalan(4), Susan C. Low(3), Adam R. Mezo(3), Chengbin Wu(2), Renee Miller(2), Donna McCarthy(2), Rongrong Zhu(2), Ling C. Santora(2), Yune Z. Kunes(2), Emma Fung(2), Tariq Ghayur(2), Susanne M. Scesney(2), Jochen Salfeld(2), Cara Fraley(2), Thomas J. Reidy(2), Alan J. Bitonti(2), Amy Tam(2), Brian J. Fennell(2), Laura Lin(2)